Y mAbs Therapeutics (YMAB) Stock
YMAB is no longer traded. Y mAbs Therapeutics was delisted from the Nasdaq in September 2025.
Prices on this page are historical; the last trade was September 15, 2025 at $8.61.
Y mAbs Therapeutics stock price history
YMAB final trading statistics
- Final close
- $8.61
- Final trading day
- Sep 15, 2025
- Market cap at delisting
- $391.22M
- Shares outstanding
- 45.44M
- Final 52-week range
- $3.55 – $16.11
- Avg. volume (final 3 mo.)
- 905,069
- All-time high (split-adj.)
- $54.26 · Dec 2020
- All-time low (split-adj.)
- $2.83 · Mar 2023
- Return since IPO
- -64.1%
- Beta
- 0.53
- Book value / share
- $1.93
- Price / book
- 4.47
Y mAbs Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $87.69M | -$29.7M | -$0.67 |
| FY2023 | $84.82M | -$21.4M | -$0.49 |
| FY2022 | $65.27M | -$96.3M | -$2.18 |
| FY2021 | $34.90M | -$56.3M | -$2.72 |
| FY2020 | $20.75M | -$119.3M | -$2.97 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey. As of September 15, 2025, Y-mAbs Therapeutics, Inc. operates as a subsidiary of SERB S.A.S.
Y mAbs Therapeutics stock FAQ
What happened to Y mAbs Therapeutics stock?
Y mAbs Therapeutics stock was delisted from the Nasdaq. Its final close was $8.61 on September 15, 2025.
Is YMAB stock still trading?
No. YMAB was delisted from the Nasdaq in September 2025 and no longer trades on a U.S. exchange.
What was the last price of YMAB stock?
YMAB closed at $8.61 on its final trading day, September 15, 2025, for a market value of about $391.22M.
What were Y mAbs Therapeutics's revenue and earnings in its last full fiscal year?
Y mAbs Therapeutics reported revenue of $87.69M and net income of -$29.7M in fiscal 2024, its last full year as a public company.
When did Y mAbs Therapeutics go public?
Y mAbs Therapeutics stock began trading on September 21, 2018.